E de Boer1,2, S Samuel3, D N French3, J M Warram1, T R Schoeb4, E L Rosenthal5, K R Zinn6. 1. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Surgery, University of Groningen, University Medical Centrum Groningen, Groningen, The Netherlands. 3. Department of Radiology, University of Alabama at Birmingham, Volker Hall G082, 1670 University Boulevard, Birmingham, AL, 35294, USA. 4. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, USA. 6. Department of Radiology, University of Alabama at Birmingham, Volker Hall G082, 1670 University Boulevard, Birmingham, AL, 35294, USA. kurtzinn@uab.edu.
Abstract
PURPOSE: The use of receptor-targeted antibodies conjugated to photosensitizers is actively being explored to enhance treatment efficacy. To facilitate clinical testing, we evaluated cetuximab conjugated to IRDye700DX (IR700) in cynomolgus macaques. PROCEDURES: Total IR700 and intact cetuximab-IR700 were measured in 51 tissues at 2 and 14 days after intravenous injection of 40 and 80 mg/kg cetuximab-IR700, respectively, and compared with an unlabeled cetuximab-dosed control group (two each per sex per time point per group). RESULTS: The IR700 retrieved from all tissues at 2 and 14 days after dosing was estimated at 34.9 ± 1.8 and 2.53 ± 0.67% of the total dose, respectively. The tissues with the highest levels of intact cetuximab-IR700 at 2 days after dosing were the blood, lung, and skin. Formalin-fixed paraffin-embedded tissue sections at 2 days after dosing showed the highest IR700 signals in the axillary lymph node, mammary gland, and gall bladder. CONCLUSIONS: Both IR700 and intact cetuximab-IR700 biodistributions were consistent with known epidermal growth factor receptor (EGFR) expression, and changes between 2 and 14 days were consistent with rapid metabolism and excretion of the cetuximab-IR700.
PURPOSE: The use of receptor-targeted antibodies conjugated to photosensitizers is actively being explored to enhance treatment efficacy. To facilitate clinical testing, we evaluated cetuximab conjugated to IRDye700DX (IR700) in cynomolgus macaques. PROCEDURES: Total IR700 and intact cetuximab-IR700 were measured in 51 tissues at 2 and 14 days after intravenous injection of 40 and 80 mg/kg cetuximab-IR700, respectively, and compared with an unlabeled cetuximab-dosed control group (two each per sex per time point per group). RESULTS: The IR700 retrieved from all tissues at 2 and 14 days after dosing was estimated at 34.9 ± 1.8 and 2.53 ± 0.67% of the total dose, respectively. The tissues with the highest levels of intact cetuximab-IR700 at 2 days after dosing were the blood, lung, and skin. Formalin-fixed paraffin-embedded tissue sections at 2 days after dosing showed the highest IR700 signals in the axillary lymph node, mammary gland, and gall bladder. CONCLUSIONS: Both IR700 and intact cetuximab-IR700 biodistributions were consistent with known epidermal growth factor receptor (EGFR) expression, and changes between 2 and 14 days were consistent with rapid metabolism and excretion of the cetuximab-IR700.
Authors: Anton G T Terwisscha van Scheltinga; Gooitzen M van Dam; Wouter B Nagengast; Vasilis Ntziachristos; Harry Hollema; Jennifer L Herek; Carolien P Schröder; Jos G W Kosterink; Marjolijn N Lub-de Hoog; Elisabeth G E de Vries Journal: J Nucl Med Date: 2011-10-11 Impact factor: 10.057
Authors: Melissa L Korb; Yolanda E Hartman; Joy Kovar; Kurt R Zinn; Kirby I Bland; Eben L Rosenthal Journal: J Surg Res Date: 2013-11-22 Impact factor: 2.192
Authors: Kurt R Zinn; Melissa Korb; Sharon Samuel; Jason M Warram; David Dion; Cheryl Killingsworth; Jinda Fan; Trenton Schoeb; Theresa V Strong; Eben L Rosenthal Journal: Mol Imaging Biol Date: 2015-02 Impact factor: 3.488
Authors: Malika Aid; Peter Abbink; Rafael A Larocca; Michael Boyd; Ramya Nityanandam; Ovini Nanayakkara; Amanda J Martinot; Edward T Moseley; Eryn Blass; Erica N Borducchi; Abishek Chandrashekar; Amanda L Brinkman; Katherine Molloy; David Jetton; Lawrence J Tartaglia; Jinyan Liu; Katharine Best; Alan S Perelson; Rafael A De La Barrera; Mark G Lewis; Dan H Barouch Journal: Cell Date: 2017-04-27 Impact factor: 41.582
Authors: Nicholas J Eustace; Joshua C Anderson; Jason M Warram; Hayley N Widden; Rune T Pedersen; Hasan Alrefai; Zeel Patel; Patricia H Hicks; William J Placzek; G Yancey Gillespie; Anita B Hjelmeland; Christopher D Willey Journal: Oncogene Date: 2020-10-19 Impact factor: 9.867